Stock 600664 HARBIN PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Harbin Pharmaceutical Group Co., Ltd.

Equities

600664

CNE0000009T3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.1 CNY +2.99% Intraday chart for Harbin Pharmaceutical Group Co., Ltd. +2.99% -7.46%
Apr. 25 Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 11 Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 10,053 9,502 7,997 8,940 7,599 8,445
Enterprise Value (EV) 1 8,259 9,499 8,874 9,661 7,315 7,242
P/E ratio 28.2 x 190 x -7.42 x 23.7 x 16.7 x 20.9 x
Yield - - - - - -
Capitalization / Revenue 0.93 x 0.8 x 0.74 x 0.7 x 0.55 x 0.55 x
EV / Revenue 0.76 x 0.8 x 0.82 x 0.75 x 0.53 x 0.47 x
EV / EBITDA 9.5 x 17.6 x -20 x 13.5 x 9.05 x 8.35 x
EV / FCF 18.2 x -19.7 x -21.3 x 31.1 x 8.74 x 8.12 x
FCF Yield 5.48% -5.07% -4.69% 3.22% 11.4% 12.3%
Price to Book 1.53 x 1.74 x 2.3 x 2.4 x 1.76 x 1.79 x
Nbr of stocks (in thousands) 2,544,953 2,507,019 2,506,955 2,518,376 2,524,514 2,520,905
Reference price 2 3.950 3.790 3.190 3.550 3.010 3.350
Announcement Date 3/15/19 4/22/20 4/2/21 4/10/23 4/10/23 4/10/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 10,814 11,825 10,788 12,802 13,809 15,457
EBITDA 1 869.2 539.4 -444.6 717 808.6 867.6
EBIT 1 459.8 152.5 -803.3 447.8 557.9 620.4
Operating Margin 4.25% 1.29% -7.45% 3.5% 4.04% 4.01%
Earnings before Tax (EBT) 1 587.7 307 -968.6 630.5 701.2 650.5
Net income 1 346.1 55.81 -1,078 371.1 464.4 395.3
Net margin 3.2% 0.47% -9.99% 2.9% 3.36% 2.56%
EPS 2 0.1400 0.0200 -0.4300 0.1500 0.1800 0.1600
Free Cash Flow 1 452.6 -481.9 -416.3 311 837.2 891.9
FCF margin 4.19% -4.08% -3.86% 2.43% 6.06% 5.77%
FCF Conversion (EBITDA) 52.08% - - 43.37% 103.54% 102.79%
FCF Conversion (Net income) 130.76% - - 83.8% 180.29% 225.64%
Dividend per Share - - - - - -
Announcement Date 3/15/19 4/22/20 4/2/21 4/10/23 4/10/23 4/10/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 877 721 - -
Net Cash position 1 1,794 2.42 - - 284 1,203
Leverage (Debt/EBITDA) - - -1.972 x 1.006 x - -
Free Cash Flow 1 453 -482 -416 311 837 892
ROE (net income / shareholders' equity) 5.87% 1.99% -21% 9.75% 10.9% 9.15%
ROA (Net income/ Total Assets) 2.25% 0.78% -4.12% 2.27% 2.65% 2.82%
Assets 1 15,418 7,146 26,135 16,369 17,498 14,040
Book Value Per Share 2 2.590 2.180 1.390 1.480 1.710 1.870
Cash Flow per Share 2 0.9000 0.2700 0.3600 0.6100 0.9600 1.210
Capex 1 114 39 118 76.7 89.6 86.5
Capex / Sales 1.06% 0.33% 1.1% 0.6% 0.65% 0.56%
Announcement Date 3/15/19 4/22/20 4/2/21 4/10/23 4/10/23 4/10/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HARBIN PHARMACEUTICAL GROUP CO., LTD. Stock Harbin Pharmaceutical Group Co., Ltd.
-7.46% 1.08B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600664 Stock
  4. Financials Harbin Pharmaceutical Group Co., Ltd.